Acute myeloid leukemia characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis. CBF-AML accounts for 12 to 15 percent of acute myeloid leukemia cases in adults. The disease is core binding factor acute myeloid leukemia (EFO_1002001). Also known as: CBF-AML.